A Study to Determine Serum and Urine Reference Ranges in Patients with Normal Renal Function Being Administered Gadobutrol for an Enhanced Magnetic Resonance Imaging (MRI)


About this study

The primary purpose of this study is to determine the serum and urine gadolinium reference ranges in patients with normal renal function being administered Gadobutrol for an enhanced MRI exam.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults 18 years or older.
  • Normal renal function:
    • Serum creatinine <1.4 mg/dL; or
    • Glomerular filtration rate; ≥60 mL/min.
  • No gadolinium-enhanced MRI in last 6 months.
  • Scheduled to undergo a gadobutrol-enhanced MRI and willing to come back for blood and urine collections at various time points (e.g. pre-MRI and 1, 3, 7, 14, 28, 56, and 84 days post-MRI.

Exclusion Criteria: 

  • Any of the above criteria not met.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Paul Jannetto, Ph.D.

Open for enrollment

Contact information:

Katelyn Reed B.S., M.H.S.

(507) 284-0503


More information


Publications are currently not available

Mayo Clinic Footer